The most important form of toxicity associated with the use of plicamycin consists of a dose-related bleeding syndrome which usually begins with an episode of epistaxis. Plicamycin crosses the blood-brain barrier; the concentration found in brain tissue is low but it persists longer than in other tissues.
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Trastuzumab | The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Plicamycin. |
| Margetuximab | The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Plicamycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plicamycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Plicamycin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Plicamycin. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plicamycin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Plicamycin. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Plicamycin is combined with Etrasimod. |